GT Biopharma, Inc.

Stage 2 · Advancing · week 7

As of Oct 22, 2026, GT Biopharma is in Stage 2, the uptrend phase, now in week 7 (since Sep 9, 2026). It closed at $5.52, 52.5% below its 52-week high and above its 200-day average, which is rising.

$5.52

+1.37% today

$11.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is GTBP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 20w

S4 41w

S4 21w

S4 19w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 20w → S1 2w → S4 41w → S1 12w → S4 13w → S1 7w → S2 6w → S3 1w → S4 21w → S1 5w → S4 19w → S1 7w → S4 5w → S1 1w → S2 6w current

Total tracked: 165 weeks across 15 stage runs.

GTBP among Biotechnology1st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%

vs 52W High

-52.5%

$0.24 lo$11.63 hi

52.5% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 7

1w13w26w

Week 7, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

269.4%

200 DMA: $1.49 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.29x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-22.3%

+1603.7%

+1437.6%

YTD

+575.6%

+689.7%

Scan Membership

Breakout Watch

Latest: 2025-06-16

4 appearances in last 60 days. First seen: 2020-05-07.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 7 · Vol 0.29x

2026-10-21S2

Wk 7 · Vol 0.69x

2026-10-20S2

Wk 6 · Vol 0.20x

2026-10-19S2

Wk 6 · Vol 0.11x

2026-10-16S2

Wk 6 · Vol 0.21x

2026-10-15S2

Wk 6 · Vol 0.24x

2026-10-14S2

Wk 6 · Vol 0.15x

2026-10-13S2

Wk 5 · Vol 0.10x

2026-10-12S2

Wk 5 · Vol 0.13x

2026-10-09S2

Wk 5 · Vol 0.14x

2026-10-08S2

Wk 5 · Vol 0.10x

2026-10-07S2

Wk 5 · Vol 0.06x

Moving averages & range

50 DMA

$4.64

200 DMA

$1.49

52W High

$11.63

52W Low

$0.24

5D Low

$5.45

Resistance levels (recent highs)

20d High

$7.36

60d High

$11.63

120d High

$11.63

250d High

$11.63

Next resistance

+33.3%

to 20d High

ROE

-113.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.8

GT Biopharma: quick answers

What stage is GT Biopharma in?

As of Oct 22, 2026, GT Biopharma (GTBP) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 9, 2026 and is in week 7. What the four stages mean

Is GT Biopharma in an uptrend?

Yes. GT Biopharma is in a Stage 2 uptrend. It trades 269.4% above its 200-day average, which is rising.

How far is GT Biopharma from its 52-week high?

GT Biopharma closed at $5.52 on Oct 22, 2026, 52.5% below its 52-week high of $11.63. Its 52-week low is $0.24.

How has GT Biopharma performed over the past year?

As of Oct 22, 2026, GT Biopharma is up 689.7% over the past year and up 575.6% so far in 2026.

Which sector and industry is GT Biopharma in?

GT Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.